Elucidating a continuum of epithelial-mesenchymal transition (EMT) and mesenchymal-epithelial transition (MET) states in clinical samples promises new insights in cancer progression and drug response. Using mass cytometry time-course analysis, we resolve lung cancer EMT states through TGFβ-treatment and identify through TGFβ-withdrawal, an MET state previously unrealized. We demonstrate significant differences between EMT and MET trajectories using a novel computational tool (TRACER) for reconstructing trajectories between cell states. Additionally, we construct a lung cancer reference map of EMT and MET states referred to as the EMT-MET STAte MaP (STAMP). Using a neural net algorithm, we project clinical samples onto the EMT-MET STAMP to characterize their phenotypic profile with single-cell resolution in terms of our in vitro EMT-MET analysis. In summary, we provide a framework that can be extended to phenotypically characterize clinical samples in the context of in vitro studies showing differential EMT-MET traits related to metastasis and drug sensitivity. 
INTRODUCTION
Malignant cells often hijack biological processes that are utilized by their normal cell counterparts 1 . One example is the epithelial-mesenchymal transition (EMT), a developmental program critical to embryogenesis and wound healing 2, 3 . Upon EMT initiation, epithelial cells undergo dramatic biochemical and morphological changes, including loss of polarity, loosening of tight and adherent junctions and acquisition of migratory and stem-like traits 4 . EMT is a dynamic process and under specific conditions is reversible (mesenchymal-epithelial transition, MET), highlighting a phenotypic plasticity that has been observed in both normal and malignant cells 3 .
The clinical significance of EMT in cancer is well documented, although controversial 5 . Mesenchymal signatures are indicators of poor prognosis in various adenocarcinomas, including lung 6, 7 . In addition, several studies have demonstrated the role of EMT in drug response and resistance 8, 9 by offering evidence that EMT signatures can be of prognostic and therapeutic value. However, because most of these cancer-related EMT studies are based on bulk gene expression data from clinical specimens, it is often unclear whether clinical EMT signatures originate from mesenchymal malignant cells as opposed to tumor stromal cells (e.g. fibroblasts) that express EMT canonical markers. Furthermore, malignant cells with a purely mesenchymal phenotype appear to be a rare occurrence with a small chance of clinical observation 10 , thus, the existence of such malignant cells is debated.
Adding to the complexity in understanding the clinical significance of EMT is the recognition that EMT is not a binary process (strictly defined by epithelial and mesenchymal states), but instead a continuum of states where transitioning cells exhibit partial EMT phenotypes with both epithelial and mesenchymal features. Partial EMT phenotypes have been observed in clinical cancer specimens and negatively correlate with survival 9, 11 , but are poorly understood. Several recent studies have attempted to better define EMT states using single-cell approaches, however they were primarily focused on preclinical models or clinical samples without bridging the two. Pastushenko et al. demonstrated the existence of partial EMT states in mammary and skin cancer by partial EMT states in clinical ovarian cancer samples with mass cytometry 13 . While these studies provide important insights, they did not directly relate their findings to EMT states that have been well characterized in cell lines or preclinical reference in vitro models. On the other hand, mass cytometry was used to study drug perturbations on TGFβ-induced EMT in mouse epithelial cancer cells 14 and sc-RNAseq was used to study TGFβ-induced EMT in human breast epithelial cells 15 , but neither of these studies provided a means to assess the clinical relevance of their respective findings.
In this study, we use high-dimensional single-cell analysis, to identify and characterize EMT states observed in primary lung cancer clinical specimens in terms of the spectrum of states observed in well-established lung cancer cell lines. Specifically, through mass cytometry time-course analysis of TGFβ-modulated EMT and
MET in lung cancer cell lines, we identify a continuum of EMT and MET states with which we create an EMT-
MET STAte MaP (STAMP). In addition, we develop and apply a novel computational trajectory analysis, the TRAjectorty of CElls Reconstruction (TRACER) algorithm, that compares state transitions in EMT and MET.
Finally, we develop and apply a machine learning algorithm to project malignant cells from clinical samples onto the EMT-MET STAMP in order to assess clinically relevant EMT and MET states in terms of our in vitro time-course analysis. Use of the EMT-MET STAMP, informed by our trajectory analysis, provides a new means to distinguish whether cells are undergoing EMT or MET and thereby has the potential to identify new phenotypic tumor properties, and inform treatment strategies, given that cells undergoing EMT or MET have been shown to exert differential drug sensitivities 9, 16 .
RESULTS

Phenotyping and ordering epithelial, partial and mesenchymal canonical EMT states in lung cancer cell lines through TGFβ single-cell time-course analysis
To study the spectrum of EMT states in lung cancer cells, we used TGFβ for EMT induction. First, we examined TGFβ responsiveness of 3 NSCLC cell lines (A549, H3255, HCC827) towards bulk expression of commonly used EMT markers 4 (E-Cadherin, Vimentin, CD44) (Fig. 1A) . A549 cells expressed high levels of both epithelial (E-Cadherin) and mesenchymal (Vimentin, CD44) markers before TGFβ treatment, thereby displaying partial EMT (pEMT) characteristics under basal conditions. With treatment, A549 cells exhibited loss of E-Cadherin and acquired morphological changes associated with a more mesenchymal phenotype (Fig. 1A, Supplementary Fig.1 ). H3255 cells exhibited primarily epithelial features at basal conditions and largely retained their epithelial morphology and protein expression with TGFβ treatment without displaying EMT changes (Fig. 1A, Supplementary Fig.1 ). The HCC827 cell line displayed strong epithelial features at basal conditions and underwent dramatic EMT marker and morphology changes with treatment ( Fig. 1A-B) , hence was chosen as the exemplary cell line for our EMT time-course studies.
Morphological heterogeneity was observed in HCC827 cells during EMT, as evidenced by confocal imaging (Fig.1B) . pEMT phenotypes (E-Cadherin + , Vimentin + ) were readily observed in enlarged cells on the periphery of epithelial islands (Fig.1B (c) ). Mesenchymal (M) cells (E-Cadherin -, Vimentin + ) appeared either enlarged and elongated or small and spindle-shaped ( Fig. 1B (d) , blue and red arrows respectively). Intriguingly, cells that were not incorporated in epithelial islands expressed Vimentin even in the absence of exogenous TGFβ, demonstrating that cell density likely affects EMT status (Fig.1B (b) ). This finding was corroborated when we examined EMT in HCC827 cells with flow cytometry under varying seeding conditions that controlled confluency ( Supplementary Fig. 1 ). This is consistent with previous reports for normal epithelial cells 17 , but extended here for lung cancer cells. In particular, in sub-confluent conditions, a significantly larger number of cells expressed high Vimentin, of which a subpopulation showed decreased E-Cadherin levels. Transition was also reflected by gradual changes in CD44 and CD24, patterning 4 readily observed EMT states ( Supplementary   Fig. 1 ), characterized by progressive increase of CD44. CD24 decreased in only a small subset of cells (CD44 hi /CD24 lo ), a phenotypic state which has been proposed to be cancer-stem-cell-like (CSC-like) 4, 18 .
To adequately capture EMT states, we optimized a TGFβ time-course during which we kept confluency consistent by re-seeding cells at each experimental time point. Cells efficiently underwent EMT within 10 days of TGFβ treatment (Fig.1C, top images) . Morphological transition was accompanied by changes in E-Cadherin, Vimentin, CD44 and CD24 expression (Fig. 1C, biaxial (Fig. 1D, Supplementary Fig. 1 ). As expected, the E state was most abundant at basal conditions, and rapidly declined by day 2 of TGFβ treatment. Reduction in the E state was accompanied by a sharp increase of the pEMT state at day 2, while pEMT/M and M* states emerged at day 6, with highest numbers at day 10 ( Fig. 1E ). Mean fold expression of the 4 markers recapitulated the observed changes towards both control conditions with time and towards the E state when examined in each state separately (Fig. 2F ). E-Cadherin showed an initial increase during EMT before dropping to its lowest levels at day 10 and this was reflective of E-Cadherin levels in the pEMT state specifically. We speculate that this increase may be the result of increased surface interactions between cells of enlarged size observed during the initial stages of EMT ( Supplementary Fig. 1 ). Unexpectedly, we observed time-dependent changes in Twist, a known EMT transcription factor 19 ( Fig.1F, Supplementary Fig. 1 ). Specifically, Twist expression was highest in the pEMT state and lowest in the M* state (Fig. 2D, right) .
Mass cytometry analysis provides deep single-cell phenotyping of TGFβ treatment and withdrawal by capturing composition and timing of canonical EMT states in lung cancer cells
For a deeper characterization of the canonical EMT states described above, we performed a mass cytometry time-course experiment on HCC827 cells where TGFβ was added for 10 days and subsequently withdrawn to observe EMT and MET respectively (Schematic Fig. 2A ). For optimal confluency conditions, at each time point, cells were collected for both mass cytometry analysis and re-seeding for subsequent time points. In total, 28 markers were measured per cell and were chosen based on literature-derived markers to characterize EMT states and markers that characterize proliferative, signaling and apoptotic cell status ( Fig. 2A , Supplementary Table 1) . We established consistency between flow and mass cytometry by confirming that the 4 canonical EMT states were reproduced on mass cytometry (Fig.2B, Supplementary Fig. 2 ). Mass cytometry also reproduced fold expression trends of all previously discussed markers (E-Cadherin, Vimentin, CD44, CD24, Twist) in the identified pEMT, pEMT/M and M* states when compared to E state (Fig. 2C, Supplementary Fig.   2 ). Upon TGFβ withdrawal, a proportion of cells that had undergone EMT returned to an epithelial state, an observation supported by canonical EMT marker expression and morphological assessment ( Fig. 2B-C) .
Mass cytometry analysis further enabled us to examine changes of additional markers alongside the canonical EMT markers (Fig. 2D, Supplementary Fig. 2 ). Keratins and other epithelial cell surface markers (e.g. MUC1, TROP2) showed expected decreases during EMT and subsequent return to basal levels following MET. Most signaling and proliferative markers rapidly increased in expression at day 2 under TGFβ treatment, and subsequently decreased by day 10 in TGFβ. Decreased expression of these markers was sustained during the first 2 days of withdrawal, time points for which M and M* cells were at highest numbers. Specifically, this pattern was observed for pSMAD2/3, a key TGFβ signaling molecule 20 , as well as for pEGFR and pS6, suggesting that signaling is downregulated in the M state. When we examined pEGFR and pS6 levels separately in the 4 canonical EMT states, we found that the M* state was negative for both ( Supplementary Fig. 2 ). This observation is consistent with studies that have associated EMT with tyrosine kinase inhibitor (TKI) resistance 8 and low p-mTOR activity with stem cell maintenance 21 . We also observed an increase of PDL-1 levels during EMT, substantiating reports that link EMT and tumor immune evasion 22 . Among the measured EMT transcription factors, apart from the transient activation of Twist, we did not detect significant expression levels of Snail or Slug. However, Oct3/4 and Nanog transcription factors showed a substantial increase in expression throughout the EMT time-course; this observation is consistent with a lung adenocarcinoma study where coexpression of Oct3/4 and Nanog were found to be critical for EMT 23 . Supplementary Fig. 2 ) and published reports 21, 30 .
Construction of an EMT-MET STAte MaP (STAMP) and TRAjectory of CElls Recontruction (TRACER) analysis identifies distinct EMT and MET trajectories and state transition dynamics in lung cancer cells
Apart from visualizing the phenotypic, time-dependent properties of EMT and MET states, our ultimate goal was to construct a EMT-MET STAte MaP (STAMP) for inferring the presence of our 8 derived EMT and MET states in lung cancer clinical specimens with single-cell resolution. To construct the EMT-MET STAMP, we first generated a 2D t-SNE projection of our derived EMT and MET states from our TGFβ mass cytometry study. Next, to define regions of the map most uniquely associated with each state, we determined the highest density region per state per sampling time and estimated its respective centroid. Given that transition is a continuum of EMT states with considerable overlap, we employed Voronoi and Convex Hull analysis 31 to achieve density-driven segmentation of the EMT t-SNE landscape; each segment corresponding to an identified EMT/MET phenotypic state at its peak during our time-course analysis ( Fig. 4A-B and Supplementary Fig. 3,   5 ). Analysis of cell density over time on the EMT-MET STAMP confirmed our previous assessment that MET differs from EMT and is specifically characterized by the appearance of the pMET state at the 2-day withdrawal time point ( Fig. 4C ). However, it also revealed the possibility that cells that belong to states pEMT2 and pEMT3 exhibit plasticity that enables them to follow the same state trajectory back toward pEMT1 and E states under TGFβ withdrawal. This observation is heuristically demonstrated in a density-driven assessment of transitions within the 2D map of EMT-MET states, depicted in Fig. 4D . When we applied the pseudotime/cell lineage computational tool Slingshot 32 to this data, it independently resolved the trajectory that involves the appearance of the pMET state during withdrawal ( Supplementary Fig. 5 ), however, it did not fully capture our empirical observations of likely state transitions.
To more rigorously assess the potential state transitions, we developed a novel computational trajectory reconstruction algorithm, TRACER (Supplementary Fig. 3 and Methods) that does not rely on pseudotime assumptions and allows branching. We assumed that EMT and MET are classical Markov processes 33 with transition probabilities that are constant between the states within EMT and MET but can differ when comparing EMT and MET. However, because our observations of the proportion of cells in each state are made at discrete, non-uniform time points, and because we do not observe the trajectories of individual cells, we cannot employ standard methods to estimate for the state transition probabilities 34 . Also, because the number of states is relatively large compared to the number of observations, we employ sparsity assumptions 35 . We modeled the state transition probabilities p jkt between states j and k at time t by imposing sparsity penalties on p jkt for j not equal to k, but no penalty on p jjt , with the idea that there is no cost for staying in a state, but switching between states is discouraged. Under these assumptions, EMT and MET state transition probabilities can be estimated by convex optimization, with the sparsity parameter λ selected through cross-validation. We applied our model separately for the EMT and MET time points and, through bootstrap analysis, we generated a distribution of the transition probabilities between states under EMT and MET, as shown in Fig. 4E . In general, the bootstrap analysis shows less non-zero state transition probabilities under MET compared to EMT, clearly demonstrating that the transition between M and pMET states is unique to MET. The medoid networks for EMT and MET are provided in Fig. 4F . Interestingly, during MET, all cells transitioning from either a pEMT or the pMET state are estimated to transition through the pEMT1 state before becoming epithelial. These results demonstrate statistically significant differences between EMT and MET trajectories as well as bidirectionality (plasticity) between certain states (e.g. between states pEMT1 and pEMT2).
Projection onto EMT-MET STAMP using a neural net algorithm serves as a means to assess EMT-MET states in independent samples and is verified using NSCLC cell lines
Given the wide range of phenotypic, and presumably functional, EMT-MET states across NSCLC cell lines, we tested whether our EMT-MET state map could serve as a reference to reconcile known heterogeneity between cell lines and experiments. To project independent samples onto the EMT-MET STAMP, we trained a neural net algorithm 36, 37 that predicts the bivariate t-SNE outputs (i.e. tSNE1 and tSNE2) of our EMT-MET STAMP in terms of the selected 6 clustering markers (Supplementary Fig. 3 and Methods). We verified the performance of our neural net mapping function using lung cancer cell lines, which have known features. First, we projected independently analyzed TGFβ HCC827 samples, and these matched previously observed mappings (Fig. 5A, left). Next, we projected two independent NSCLC cell lines (A549, H3255), given that we had prior knowledge of their EMT status (Fig.1A) . As expected, A549 cells mapped onto the pEMT3 and M region in control conditions and extended into the M region upon TGFβ treatment (Fig. 5A, middle) . On the other hand, and in agreement with our previous findings, H3255 cells mapped mostly on E2, and to a lesser degree on pEMT1, with almost no changes upon TGFβ treatment (Fig. 5A, right) . These map projections were consistent with morphological assessment and respective E-Cadherin/Vimentin and CD44/CD24 expression profiles ( Fig. 5B-C ).
Projection of clinical NSCLC samples onto the EMT-MET STAMP demonstrates the existence of the partial and full EMT and MET states
cell resolution by projecting them onto the EMT-MET STAMP using our neural net algorithm described above. Fig. 6 ). The specimens harbored different mutations and their differentiation status was graded as poor, moderate or well in the pathology report.
Tumor size and smoking history were also recorded ( Cases No. 1, 2 and 3 (all EGFR mutated) mapped primarily onto epithelial regions with some extent into the pEMT1 regions, and expressed, as expected, higher pEGFR levels ( Supplementary Fig. 7 ). Interestingly, this mapping is consistent with EGFR mutated cell lines HCC827 and H3255 in basal conditions and confirmed by morphological assessment (Supplementary Fig. 6 ). Case No. 3, harboring an additional TP53 mutation, broadly extended into the pEMT regions, primarily occupying the pEMT3 region, with a small fraction of cells in the M and pMET regions. Case No. 4 and 5, harboring TP53 and KRAS mutations respectively, showed the most partial EMT features, occupying the pEMT2 and pEMT3 regions (and to a lesser degree M), reassuringly similar to A549 cells that are also KRAS mutated (Fig. 5) . Interestingly, Case Nos. 4 and 5, in comparison to Case Nos.
1-3, were graded as poorly differentiated and showed higher levels of immune infiltration (Fig. 6 , Supplementary Fig. 6 ), suggesting the association of these clinical features with specific EMT states. While a larger sample size is necessary to solidify conclusions, these results are consistent with studies reporting correlations between NSCLC mutations and immune infiltration with EMT status 22, 38 . Overall, we show that our EMT-MET STAMP can be utilized to score and interpret clinical specimen data towards EMT and MET state heterogeneity and that similar approaches can be extended to phenotyping a range of cellular processes that involve cell state transitions in various types of cancers. Fig. 6 ). Even though we did not detect expression of other EMT-specific transcription factors (i.e., Slug, Snail, Zeb1, Supplementary Fig. 1 ), we cannot exclude the possibility that these may be activated in
DISCUSSION
earlier EMT time points not tested here.
Our time-course analysis of MET is a key aspect of our study. MET is thought to be critical to the establishment of secondary distant tumors. Yet, compared to EMT, MET is less studied, particularly with single-cell resolution. Some studies have shown that EMT is reversible among cells in partial EMT states but not necessarily among cells that have become mesenchymal, although this seems to be cell-type dependent 42, 43 .
Even so, for cells undergoing MET, it is unclear whether the MET trajectory mirrors or differs from the EMT trajectory. Differing trajectories that we found is evidence of hysteresis, a phenomenon in which the dependence of a future state depends on its history. Several mathematical modeling studies have provided evidence of hysteresis when comparing EMT and MET, however these were based on gene expression data or
were not associated with specific phenotypic states 27, 28 . By analyzing mass cytometry time-course data using our novel algorithm TRACER, we find statistically significant evidence of hysteresis. In particular, we showed that some mesenchymal cells undergo MET utilizing a trajectory not observed under EMT and transit through a newly identified state that we defined as pMET. More specifically, our study supports two possible scenarios. In the first scenario, cells in the M state have undergone such significant (presumably epigenetic) changes that in order to undergo MET, they utilize a different trajectory. Consistent with this, is the likelihood that M cells are more stable than partial EMT cells, given that a significant proportion of cells failed to undergo MET after TGFβ withdrawal. Moreover, we found that if cells have not efficiently undergone EMT (majority of cells transition to pEMT and not M states), most of them are able to undergo MET (Supplementary Fig. 5 ). In the second scenario, if during conditions that promote MET a cell is in a partial EMT state, it utilizes a mirrored trajectory back to an epithelial state. Supporting this, the medoid network from TRACER, and the bootstrap analysis, detected bidirectionality between the partial EMT states (Fig.4E-F supporting not only the necessity of a larger scaled study, but the importance of a well-defined EMT reference map. Perhaps the most intriguing aspect of projecting onto the EMT-MET STAMP, is the promise it holds for future therapeutic efforts. EMT and MET have been correlated with drug resistance 8, 45, 46 . Therefore, being able to assess malignant cells from clinical samples in terms of specific EMT and MET states can be informative.
For instance, some studies have suggested that inducing MET could be beneficial by restoring sensitivity to TKI inhibitors 16, 47 . Indeed, our data showed that pEGFR signaling was lowest in the M (specifically M*) state, whereas in cells undergoing MET, pEGFR levels increased ( Supplementary Fig. 2-5 ), which would hypothetically constitute TKI sensitivity. Therefore, depending on the situation and timing, one may choose to target or induce the pMET state, and having a proteomic-based EMT-MET map featuring targetable markers could benefit such efforts. To this end, our map showed that we could theoretically distinguish whether a specimen had cells undergoing EMT or MET, and this alone could have implications on clinical assessment.
Specifically, our data show that if cells are in the pMET state, they significantly differ from M cells primarily in terms of MUC1 expression, a molecule that is being studied as a therapeutic target in lung cancer 48 . None of our clinical specimens mapped significantly onto the pMET region, barring Case No 3. This was expected, because such cells are more likely present in metastatic and not primary tumors; however, this does not negate the possibility that cells within any given tumor may undergo MET depending on spatiotemporal conditions. In addition to predicting drug resistance, an EMT-MET map may have utility for evaluating disease progression and drug response during therapy at the individual patient level. For example, analyzing malignant pleural effusions has been proposed as means to evaluate disease status and EMT markers have been detected in lung cancer pleural effusions 49, 50 .
Our study proposes a novel approach for interrogating and mapping EMT states but has its limitations.
Although here we chose TGFβ to induce EMT in lung cancer cells, it is well known that EMT can be triggered by a variety of conditions including hypoxia and drug treatments 51 . To expand the concept that we presented, it would be reasonable to test and compare different modes of EMT induction and examine how these would affect the constructed state map, or the projections onto it. However, it has been reported that the EMT phenotypes acquired under different inducers are quite common, barring some signaling pathway differences 51 ;
suggesting that our map, that was built on canonical EMT markers, could have broader use. Moreover, the fact that common EMT phenotypes exist despite the variety of signaling/mutational underlying backgrounds, justifies our choice to build our map with the HCC827 cell line, as it portrayed a complete continuum of EMT-MET states. Nevertheless, constructing an EMT-MET state map that incorporates different mutational backgrounds and modes of induction is a worthy pursuit. It is important to note that projecting individual specimens on a reference map differs from traditional approaches where multiple samples are pooled for analysis; allowing each specimen to be examined within its own heterogeneous identity. Also, by using singlecell proteomic data, our approach differs from similar studies that have employed basic concepts from machine learning to classify and diagnose clinical samples based on gene profiling alone 36, 52 . Finally, our work can be extended to multiplexed imaging 53 
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METHODS
Cell line Studies
HCC827, H3255 and A549 NSCLC adenocarcinoma cell lines were a generous gift from Dr. Parag Mallick and were grown in RPMI and DMEM media respectively, supplemented with 10% fetal bovine serum (FBS) and 5% antibiotic solution (penicillin/streptomycin), at 5% CO2 and 37 o C.
Human Studies
Clinical aspects of this study were approved by the Stanford Institutional Review Board in accordance with the Declaration of Helsinki guidelines for the ethical conduct of research. All patients involved provided informed consent. Collection and use of human tissue was approved and was in compliance with data protection regulations regarding patient confidentiality. Following surgical resection of primary tumors from five patients at Stanford hospital, NSCLC adenocarcinoma specimens were immediately processed in order to achieve single-cell suspensions for mass cytometry analysis.
EMT Induction in NSCLC cell lines
For optimal EMT induction cells were seeded in 100mm tissue culture plates at 750 000 cells/plate for 24hrs
and then switched to 2% FBS media for 24hrs. Cells were then treated with 5ng/mL TGFβ (R&D, #240-B/CF) for various time points in 2% FBS media. To keep cell density a non-critical factor for EMT induction, cells 
Immunoblotting
Cells were lysed by adding lysis buffer (50mM Tris, pH 8.0, 2% SDS, 1x protease inhibitor cocktail, 25mM
NaF, 100uM Na 3 VO 4 , 5mM EGTA and mM EDTA) to adherent cells (using a cell scraper). Lysates were then sonicated on ice in order to shear DNA and reduce viscosity. To pellet cellular debris, lysates were centrifuged at 14000 rpm at 4 o C for 10 minutes and supernatants were transferred to fresh tubes. Protein quantification was performed using the Pierce BCA protein assay kit (Thermoscientific) and equal amounts of total protein were subjected to standard electrophoresis conditions. Separated protein lysates were transferred to PVDF membranes (Millipore #IPVH00010), which were subsequently rinsed in TBST (Tris-buffered saline, 0.1% Tween 20) . Blocking non-specific binding sites was performed using 5% (w/v) nonfat dry milk in TBST for 1hr Membranes were then washed three times in TBST, 5 minutes each time and incubated with appropriate secondary antibodies in blocking solution for 1hr at room temperature. Following three 5-minute washes with TBST, immunoreactivity was visualized using a standard ECL detection system.
Phase-Contrast and Confocal Fluorescence Microscopy
Phase-contrast images of cells undergoing EMT were obtained with a Zeiss Axiovert 40C microscope (5x, 10x, 20x objectives) equipped with an Axiocam 105 color camera and processed using the Zen 2 software. For confocal fluorescence microscopy, HCC827 cells that were previously grown in either control conditions (absence of TGFβ, 2% FBS RPMI media) or in presence of TGFβ (5ng/ml) for a number of days were seeded on coverslips placed in 6-well plates at a density of 125 000 cells per well. Treatment with TGFβ was continued depending on time-course requirements. Following treatment, cells were rinsed with HBSS and subsequently with ice cold 5% BSA/PBS twice. Cells were then fixed with paraformaldehyde solution (PFA, EMS, #15710) at a final concentration of 4% for 15 minutes at room temperature followed by 3 washes with PBS.
Permeabilization was performed with 0.1% Triton x100 (Sigma Aldrich) for 10 minutes at room temperature followed by 3 washes with PBS. Blocking was performed by incubating cells with 5% BSA/PBS solution for 30 minutes at room temperature. Cells were then incubated with fluorophore conjugated primary antibodies for 1 hr in the dark (Alexa 488 Vimentin Antibody (BD, #562338) and Alexa 647 E-Cadherin Antibody (BD, # 324112)). Following 3 washes with PBS, cells were mounted in Gold antifade reagent with DAPI (Molecular Probes P36935). Images were obtained and analyzed using the inverted Zeiss LSM 880 laser scanning confocal microscope with Airyscan (40x objective) and Zen Black software respectively.
Flow Cytometry
Following treatments cells were lifted off tissue culture plates using TrypLE (Life technologies, #12605-010).
After counting and assessing % viability with Trypan Blue exclusion, 1 x 10 6 cell aliquots per condition were fixed by adding PFA at a final concentration of 1.6% for 10 minutes at room temperature. Cells were then Cell viability was determined with trypan blue staining prior fixation (to ensure high viability before processing). All samples analyzed were > 80% viable. Finally, cell aliquots of 0.5-1 x 10 6 cells /mL were fixed with PFA at a final concentration of 1.6% for 10 minutes at room temperature and washed twice with CSM before being stored in CSM at -80 o C until barcoding and staining procedures for CyTOF analysis.
Mass Cytometry Antibodies
Antibodies used for mass cytometry analysis, including respective information on antibody clone, vendor, metal isotope and staining concentration, are summarized in Table S1 . Aside from one antibody purchased from Fluidigm (CD104), all antibodies were conjugated to metal-isotopes in-house using the MaxPar Antibody Conjugation Kit (Fluidigm) and titrated to determine optimal staining concentrations.
Sample Processing, Mass-Tag Barcoding and Antibody Staining for Mass Cytometry Analysis
Cell line samples were processed similar to tumor samples following dissociation and as previously described 54 .
Briefly, following treatments, cells were lifted off tissue culture plates using TrypLE. Cell count and initial % viability were assessed using Trypan Blue exclusion. To assess cell viability for mass cytometry, cell pellets were briefly incubated in 1mL PBS containing cisplatin (final concentration 5 µM) for 5 minutes at room temperature. Cisplatin reaction was quenched by adding 2ml of CSM and subsequent centrifugation for 5 minutes at 500g. Cell pellets were resuspended in CSM in 0.5-1x10 6 aliquots per condition and were fixed by adding PFA at a final concentration of 1.6% for 10 minutes at room temperature. Cells were centrifuged at 500g
for 5 minutes at 4 o C to pellet cells and remove PFA and washed once with CSM. Cell pellets were resuspended in CSM and stored at -80 o C until all time-points of the same time-course or multiple clinical specimens were collected. To improve staining consistency, samples were palladium barcoded and pooled for staining as previously described 55 . In short, different combinatorial mixtures of palladium-containing mass-tag barcoding reagents in DMSO were added to each cell line or tumor sample previously resuspended in PBS-saponin solution and mixed with pipetting. Samples were incubated with barcoding reagents for 15 minutes at room temperature. Reaction was quenched with the addition of CSM followed by several washes with CSM prior to pooling all samples together to proceed with staining. Surface and intracellular antigen antibodies were separately added into two master mixes in CSM, filtered through a 0.1 µm filter (Millipore #UFC30VV00) and centrifuged at 1000g for 5 minutes to remove antibody aggregates. For tumor specimen analysis, separate staining cocktails using the same concentrations were prepared with the addition of antibodies towards CD45, FAP and CD31 for gating out immune, stromal and endothelial tumor populations respectively as previously described 13 . Samples were first incubated with surface antibody master mix for 30 minutes at room temperature. Cell samples were then washed with CSM and permeabilized with methanol for 10 minutes on ice. Apart from antibody metal isotopes listed in Table S1 , we also recorded event length, barcoding channels (102Pd, 104Pd, 105Pd, 106Pd, 108Pd, 110Pd), normalization beads (140Ce, 151Eu, 153Eu, 165Ho, 175Lu) , DNA (191Ir and 193Ir) , and dead cells (195Pt and 196Pt).
Mass Cytometry Data Processing
Normalization and single-cell debarcoding were performed through respective algorithms as described previously 55 . Debarcoded samples were uploaded as separate FCS files and analyzed on Cytobank. Cytobank software was used for traditional cytometry statistics and visualization (histograms, density plots, heatmaps and SPADE (as previously described 56 ).
QUANTIFICATION AND STATISTICAL ANALYSIS CCAST Clustering
Raw mass cytometry data from cell line TGFβ time-course experiments were arsinh transformed on Cytobank.
After gating out dead and apoptotic cells, remaining cells from all time-points were pooled together. The
CCAST-recursive partitioning-based algorithm 24 was applied assuming a minimum of 8 clusters on a subsample of ~96000 cells obtained from density-dependent down sampling 56 based on 6 EMT markers (E-Cadherin, Vimentin, CD44, CD24, MUC1 and Twist). These markers were selected using an unbiased non-parametric regression tree analysis 57 . All 6 markers were among the most statistically significant (p-value <0.001) markers that correlated independently with the top 3 principal components explaining about 50% variability in the data (See Table S2 ). Final selection of the 6 markers was based on EMT biological relevance. The CCAST analysis resulted initially in 13 clusters (see Supplementary Fig. 4 ) of which 5 were excluded from downstream analysis based on a pre-set threshold of each cluster ≥1% of total number of cells analyzed. All data processing and clustering analysis was performed in R.
Force-Directed Layout Visualization of CCAST Clusters
To visualize the spatiotemporal dynamics of EMT and MET processes in HCC827 cells treated with TGFβ, we used Vortex, a graphical tool for visualizing clusters generated from multiparametric datasets. Specifically, we created single-cell force-directed layouts. The resulting graph was constructed specifically on the pre-identified 8 CCAST clusters. We utilized Vortex to only implement edge connections between subsequent time points (similar to the FLOW-MAP algorithm 58 ). The force-directed layout graph was used to assess the EMT/MET phenotypic continuum in terms of timing and the expression profiles of all 27 markers measured with mass cytometry. The graph is built by repulsing all cells with forces proportional to how dissimilar they are in multidimensional protein expression space, while edges hold adjacent cells together by constant spring-like force 26 .
Construction of the 2D EMT-MET STAte MaP (STAMP)
Using the 6 CCAST clustering markers (E-cadherin, Vimentin, Twist, CD24, CD44, and MUC1), we next generated a 2D-t-SNE 59 map using the Rtsne package implemented in R with a default perplexity parameter of 30. We next applied Voronoi mapping using 8 optimal center points obtained from the above CCAST clusters.
These points were obtained from cluster-specific bins with sizes estimated by varying sizes of 1 to 8 units over 
Neural Network for Projecting onto the EMT-MET STAMP
To model the non-linear structure of the underlying 2D EMT-MET state map, we constructed a single-layerhidden artificial neural network model using the above 6 markers as input and the reduced 2D t-SNE feature space as a bivariate response. Specifically, we used the 6 input expression values for each cell from the cell line samples to predict the corresponding position of each new cell onto the 2D reference map space. Projection results were visualized as bivariate scatter plots. To train the network, weights on the edges are modified to minimize the error in the output. At the end of training, the inputs which are most important in prediction have the largest weights while those that are less important have lower weights. The network was trained on 90% min-max normalized data using the ``nnet" R package and the remaining 10% was used (1) to optimize for the 11 hidden nodes needed and (2) to carry out a 10-fold cross validation on the stability of model predictions. The trained neural network was next used to project an independent HCC827 time-course repeat, A549 and H3255 34 . Also, because the number of states is relatively large compared to the number of observations, we employed sparsity assumptions 35 . We modeled the state transition probabilities p jkt between states j and k at time t by imposing sparsity penalties on p jkt for j not equal to k, but no penalty on p jjt , with the idea is that there is no cost for staying in a state, but switching between states is discouraged. Under these assumptions, the transition probabilities EMT and MET can be estimated by convex optimization, with the sparsity parameter λ selected through cross-validation. We chose by the 1-standard error rule 61 , that is, we chose the largest λ such that its error is within 1-standard error of the error of the minimizing. This leads to more parsimonious solution. Using bootstrap analysis, we provide a distribution of the transition probabilities for EMT and MET, as shown in Fig.4E . For the bootstrap analysis, we first independently sampled a multinomial distribution for cell counts in each state. We split the bootstrap sample into 2 folds. The first fold was used to estimate the sparsity parameter λ. We evaluated the estimator with the chosen λ on the second fold.
For representative EMT and MET networks, the medoid networks for EMT and MET was selected among all the bootstrap samples as the network for which the average distance to all other networks (entry-wise L1 distance between transition matrices) was smallest (Fig. 4F) . 
